You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):就HLX13(重組抗CTLA-4全人單克隆抗體注射液)與Sandoz訂立的許可協議
格隆匯 04-29 17:59

格隆匯4月29日丨復宏漢霖(02696.HK)公吿,近日,公司與Sandoz AG("Sandoz")訂立一份許可協議,據此,公司向Sandoz授出獨家許可,供其於美國、約定的歐洲地區(42個歐洲國家)、日本、澳大利亞及加拿大("區域")內及領域(定義如下)內商業化HLX13(重組抗CTLA-4全人單克隆抗體注射液)("許可產品"或"HLX13")。

HLX13是公司自主研發的伊匹木單抗生物類似藥,擬用於黑色素瘤、腎細胞癌、結直腸癌、肝細胞癌、非小細胞肺癌、惡性胸膜間皮瘤及食管鱗狀細胞癌的治療。2023年12月,HLX13在中國健康男性受試者中開展的1期臨牀研究完成首例受試者給藥。根據IQVIAMIDASTM的資料(IQVIA是全球醫藥健康產業專業信息和戰略諮詢服務提供商),2024年度,伊匹木單抗於全球範圍內的銷售額為28.73億美元。

本次與Sandoz訂立許可協議有助於深化公司產品的出海進程,進一步提升公司產品在國際市場的可及性和影響力,並有望為區域內患者提供更多治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account